Continuing its search for ophthalmic drivers, Novartis AG has in-licensed a recombinant human lubricin from Lµbris BioPharma which it hopes will become a solution for dry eye, a condition with high unmet medical need that affects more than 344 million patients globally.
The in-licensing arrangement for the product, dubbed ECF843, was announced April 6 and gives the Swiss drug maker commercial rights...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

